▼ Summary
– Bristol fusion startup Astral Systems has raised £23mn in Series A funding to scale production of medical isotopes used in cancer diagnosis and treatment.
– Unlike most fusion companies focused on future clean power, Astral already operates three commercial fusion facilities and earns revenue from research contracts.
– The company’s multi-state fusion reactors produce neutron beams to make isotopes, addressing a fragile supply chain where the UK has almost no domestic source.
– Funds will support a site at the decommissioned Berkeley Power Station, with plans to run several reactors at full capacity by end of 2026 and reach profitability in 2027.
– Astral competes with US firms like SHINE Technologies and Niowave, but argues its modular technology can produce a wider range of isotopes for the UK market.
Bristol-based fusion startup Astral Systems has secured £23mn in funding to scale up production of medical isotopes essential for cancer diagnostics and treatment. This Astral Systems £23M round backs a rare fusion company that is already generating revenue from operational reactors.
While most fusion companies focus on the long-term promise of clean energy, Astral Systems is taking a different approach,and getting paid for it today.
The first tranche of a £23mn Series A round was led by Mercia Ventures, bringing the company’s total funding past £28mn. The capital will be used to ramp up output of radioactive isotopes used in cancer scans and therapies, a market plagued by fragile supply chains and virtually no domestic UK production.
Tees River, Daphni, and Blast Club participated in the round, along with returning investors Speedinvest and Playfair. This marks a strong period for UK venture capital activity.
A fragile supply chain few know about
Over 50 million cancer scans and treatments each year depend on radioisotopes. These are produced by bombarding raw materials with neutrons inside nuclear reactors.
The problem is that most of those reactors are decades old and located in just a handful of countries. The UK produces almost none of these isotopes itself.
This is not a hypothetical risk. In 2009 and 2010, simultaneous outages at reactors in Canada and the Netherlands caused severe shortages across hospitals in Europe and North America.
What Astral actually built
Founded in 2021 by CEO Talmon Firestone and CTO Tom Wallace-Smith, Astral Systems has developed a reactor design called multi-state fusion. This device combines different fusion states within a single unit to generate intense neutron beams, which are then used to create isotopes.
Unlike the vast majority of fusion companies, Astral is already operational. It runs three commercial fusion facilities and has signed research contracts valued at over £3mn.
In partnership with McMaster University and a Brazilian nuclear research institute, Astral is developing two isotopes for targeted cancer therapy: Actinium-225 and Lead-212. The company aims to bring at least one to market by early 2027.
Why a former power station
The new funding will support a site at the decommissioned Berkeley Power Station in Gloucestershire. This location offers existing grid connections and nuclear-grade infrastructure, which are critical for scaling production.
Astral plans to operate several next-generation reactors there at full capacity by the end of 2026. The company expects to reach profitability in 2027 and grow its workforce from 23 to over 40 employees.
Two senior scientists have joined to support this expansion: NASA Laureate Theresa Benyo as chief research officer, and Mahmoud Bakr as chief scientist.
A crowded race
Astral is not the only player aiming to fill the isotope gap. In the US, SHINE Technologies has raised over $1bn and operates a large facility producing Lutetium-177. Another US firm, Niowave, uses electron accelerators instead of fusion. Both are further along commercially, but neither serves the UK market.
Astral argues its technology can produce a wider range of isotopes at a modular scale. Meanwhile, the broader fusion sector continues to pour billions into the distant goal of clean power.
“We are rewriting how we approach fusion and, in doing so, redefining what it means to be a fusion company,” Firestone said.
Lee Lindley, who led the deal at Mercia, framed the investment as a commercial opportunity rather than a scientific experiment. He called Astral “a perfect example of the bold ideas that Mercia likes to back.”
The bottom line
The potential market is substantial. The global nuclear medicine market was valued at $17.77bn in 2024 and is projected to reach $34.51bn by 2030, according to Grand View Research.
The challenge now is execution. Astral must scale novel reactors at an aging power station while hitting its 2027 profitability target.
If successful, the first commercial chapter of British fusion may begin not with clean power, but with cancer care.
(Source: The Next Web)